Compared with the SGLT2 inhibitors group, there was no evidence that the GLP-1RAs group was associated with the following outcomes: (1) the new onset of heart failure (HR 0.97; 95% CI 0.93, 1.01); (2) a composite incidence of MACE (HR 0.95; 95% CI 0.90, 1.01); or (3) a composite of cerebrovascular diseases (HR 0.99; 95% CI 0.94, 1.03). The gene discussed is SLC5A2; the disease is cerebrovascular disorder.